The FDA’s Next Psychedelic Hearing Skips the Question That Sank MDMA Therapy

On September 14, from 12:30 to 4:30 p.m. ET, FDA officials will convene at the agency’s White Oak campus in Silver Spring, Maryland — in person and by live webcast — for a public hearing called “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs.” Written comments stay open until October 5. It is the agency’s most concrete psychedelics move since a July 14 final guidance tried, on paper, to fix the problem that killed the last real application to reach its desk.

The FDA has now decided how psychedelic therapy will be delivered before any sponsor has proven, in a completed trial, that one can be trusted.

That trust problem has a name: functional unblinding. In a normal placebo-controlled trial, neither patient nor investigator is supposed to know who got the real drug. Psychedelics break that by design — one arm feels an unmistakable altered state, the other feels nothing, and both patients and therapists can usually tell which is which within the hour. That’s not a footnote. Expectation shapes outcome: a patient who knows they got MDMA is primed to report relief; a patient who knows they got saline is primed to report none. It is exactly what an FDA advisory committee flagged when it voted against Lykos Therapeutics’ MDMA-assisted PTSD therapy in June 2024, and what the agency cited weeks later in the rejection letter that followed, as Science reported at the time.

The July 14 guidance, “Psychedelic Drugs: Considerations for Clinical Investigations,” is FDA’s formal answer: active placebos that mimic some bodily sensations without the trip, mandatory blinding-integrity questionnaires, built-in expectancy controls, and a “complementary” design pairing a placebo-controlled study with a separate dose-response study that drops the placebo requirement altogether. Results, the agency says, must be “strongly persuasive and robust across study endpoints” to survive review. That’s the theory. No sponsor has run a full Phase 3 program under it yet.

Which makes the September 14 agenda notable for what it isn’t. FDA’s four stated questions are provider training and credentialing, patient safety, access, and standardizing data collection — the machinery of scaling a treatment, not validating one. Pending applications, Controlled Substances Act scheduling, and legalization are explicitly out of scope. The agency is sketching the clinic before it has the drug.

That sequencing isn’t crazy — training standards and insurance frameworks take years to build, and starting now, under the White House’s April push to accelerate psychedelic access, buys time later. But it also means the fight that actually matters — whether any company can run a psychedelic trial where blinding holds up under FDA’s new rules — hasn’t been settled. It will be decided quietly, one review division at a time, long after this hearing’s transcript is filed.